- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 25/22 - Anxiolytics
Patent holdings for IPC class A61P 25/22
Total number of patents in this class: 2502
10-year publication summary
|
44
|
62
|
120
|
164
|
149
|
170
|
195
|
189
|
198
|
147
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Takeda Pharmaceutical Company Limited | 2707 |
45 |
| Taisho Pharmaceutical Co., Ltd. | 861 |
45 |
| AstraZeneca AB | 2855 |
39 |
| F. Hoffmann-La Roche AG | 7946 |
37 |
| Hoffmann-La Roche Inc. | 3504 |
32 |
| H. Lundbeck A/S | 1247 |
27 |
| Société des Produits Nestlé S.A. | 9342 |
25 |
| Sage Therapeutics, Inc. | 374 |
23 |
| Intra-Cellular Therapies, Inc. | 414 |
22 |
| Daiichi Sankyo Company, Limited | 1879 |
18 |
| Nippon Chemiphar Co., Ltd. | 232 |
18 |
| Sumitomo Dainippon Pharma Co., Ltd. | 212 |
17 |
| Janssen Pharmaceutica N.V. | 3360 |
16 |
| The Trustees of Columbia University in the City of New York | 3600 |
15 |
| Bionomics Limited | 89 |
15 |
| Compass Pathfinder Limited | 104 |
15 |
| Glaxo Group Limited | 4136 |
14 |
| Les Laboratoires Servier | 530 |
14 |
| The Regents of the University of California | 20195 |
13 |
| Raqualia Pharma Inc. | 122 |
13 |
| Other owners | 2039 |